Remove Hospitals Remove Trials Remove Vaccine Remove Virus
article thumbnail

Cancer vaccine shows sustained improvement in survival rates

Drug Discovery World

Cancer vaccine mRNA-4157 (V940) in combination with Keytruda reduced the risk of recurrence or death by 49% in patients with resected high-risk melanoma, according to follow-up data presented at ASCO 2024. Ultimately it will contribute to survival rates improving continually over the next decades and more.” months after initial treatment.

Vaccine 148
article thumbnail

FDA approves RSV vaccine to protect babies from birth

Drug Discovery World

The US Food and Drug Administration (FDA) has approved the first vaccine for pregnant individuals to prevent respiratory syncytial virus (RSV) in infants. In infants and children, the risk of RSV-associated LRTD is highest during the first year of life.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AI identifies drug candidates for respiratory syncytial virus

Drug Discovery World

Potential new drug candidates have been identified by a respiratory syncytial virus (RSV) artificial intelligence programme, as health officials warn of a “tripledemic” of SARS-CoV-2, influenza and RSV. . The post AI identifies drug candidates for respiratory syncytial virus appeared first on Drug Discovery World (DDW).

Virus 130
article thumbnail

Covid researchers launch Monkeypox study  

Drug Discovery World

The trial will see participants receive either a 14-day course of 600 mg tecovirimat twice daily or a matched placebo treatment. As a community-based trial, participants will take the treatment or placebo in their own homes. The trial looks to include at least 500 participants in the UK. .

Research 246
article thumbnail

European Commission authorises GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for older adults

The Pharma Data

This is the first time an RSV vaccine for older adults has been granted European Marketing Authorisation. This authorisation for Arexvy means eligible adults can be vaccinated against RSV disease for the first time, reinforcing GSK’s long history of vaccine innovation. The vaccine was generally well tolerated.

Virus 40
article thumbnail

GSK’s respiratory syncytial virus

The Pharma Data

This is the first time an RSV vaccine candidate for adults has gained a positive opinion, one of the final steps in the marketing authorisation procedure prior to approval by the European Commission. There are no RSV vaccines or specific treatments currently available for older adults. Efficacy was 94.6% (95% CI, 65.9–99.9,

Virus 40
article thumbnail

Covid vaccine: Trial of new coronavirus vaccine starts in UK

The Pharma Data

A trial of a new vaccine that appears to train the immune system to fight coronavirus has begun in the UK. Early tests showed the jab, developed by US biotechnology company Novavax, leads to high levels of virus-fighting antibodies being produced. The vaccine has been tested in animals and small numbers of people already.

Vaccine 52